Diplomat to distribute SYNRIBO®, home-administered injection treatment for chronic myeloid leukemia
FLINT, Mich., May 23, 2014 /PRNewswire-iReach/ — Diplomat, the nation’s largest independent specialty pharmacy, announced that it will be distributing SYNRIBO(®) (omacetaxine mepesuccinate), now approved by the U.S. Food and Drug Administration for subcutaneous injection and home administration. SYNRIBO is a treatment for adults with chronic myeloid leukemia (CML) who are no longer responding to or are unable to tolerate two or more tyrosine kinase inhibitors (TKIs). The new labeling for the product gives prescribers the option to allow patients to administer their SYNRIBO therapy in the comfort and convenience of their own home.
Previously, patients prescribed SYNRIBO were required to travel to their doctor’s office twice a day for a two-week period to receive treatment. The administration schedule placed a burden on patients and their caregivers that created a potential barrier to treatment. According to the American Cancer Society, a little more than 10 percent of leukemia diagnoses each year are CML, which affects the blood and bone marrow.
Diplomat has an established injection training program that offers in-home nursing visits to teach patients to self-administer injectable medications. With Diplomat’s program, support for patients continues throughout their treatment to ensure continued success with subcutaneous injections.
SYNRIBO is manufactured by Teva Pharmaceutical Industries Ltd. and originally received accelerated FDA approval in October 2012, with full approval following in February 2014. SYNRIBO is the first protein synthesis inhibitor for CML that has been shown in laboratory studies to prevent the production of specific proteins Bcr-Abl and Mcl-1, which are produced by cancerous CML cells. For full prescribing information, visit the manufacturer’s website.
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Israel. They are committed to developing and manufacturing affordable generic drugs as well as specialty pharmaceuticals. Teva is the world’s leading generic drug manufacturer. The company’s specialty pharmaceuticals business focuses on CMS, respiratory oncology, pain, women’s health and biologics. For additional information, please visit tevapharm.com.
Diplomat serves patients and physicians in all 50 states as the nation’s largest independent specialty pharmacy. Headquartered in Flint, Mich., the company focuses on medication management programs for people with specialized, long-term medical needs, including cancer, HIV, hepatitis C, multiple sclerosis and many other serious or chronic conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues — always focused on increasing adherence and improving outcomes. Diplomat has accreditations with URAC, PCAB, VAWD, ASHP and ACHC. Learn more at diplomat.is.
Media Contact: Gary Rice, Diplomat Pharmacy, 810-768-9863, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Diplomat Pharmacy